Cancer immunotherapy and cancer vaccines have long generated excitement for their potential as a key element of effective cancer treatments. This excitement reached new levels at 2012 annual meeting of the American Society of Clinical Oncology (ASCO), where positive data from numerous clinical studies of cancer immunotherapies was presented and discussed. Among this presented data were results from a study of one of Immunovaccine’s clinical-stage cancer vaccines.
Cancer vaccines hold the greatest promise as adjuvant treatments, when tumor burden is low and the vaccine is used to eradicate minimal residual disease following first-line treatments. Most of these vaccines are being developed with the expectation that they will be used in combinations with surgery, chemotherapy and radiation treatments to improve the current standards of care in treating cancer.
Immunovaccine is currently actively advancing two clinical-stage cancer vaccines based on the company’s novel DepoVax technology. The company’s efforts in this area are guided by the following three key principles:
Immunovaccine is committed to advancing and systematically decreasing the risk associated with its cancer vaccine programs by generating strong clinical data that justify further development of the programs. To learn more about Immunovaccine's clinical-stage vaccine programs please visit the following pages:
Watch this MRI video to see how a DepoVax-based vaccine candidate eliminates small tumors in real time or download the MRI Visualization of Depot Vaccines poster.